骨髓增生异常综合征患者骨髓中端粒保护蛋白TIN2和POT1的mRNA表达

摘要

This study was purposed to explore the relationship between the mRNA expression of telomere protection protein TIN2 and POT1 and the pathogenesis of myelodysplatic syndrome (MDS). The expression of TIN2 and POT1 genes at the mRNA levels were detected by real-time fluorescence quantitative PCR in 51 patients with MDS and 10 normal controls. The results showed that the mRNA expressions of TIN2 in RA/RARS/RCMD/MDS-U, RAEB-1 and RAEB-2 groups according to the World Health Organization criteria were significantly higher than that in the controls (P <0. 05); the mRNA expressions of POT1 in RA/RARS/RCMD/MDS-U, RAEB-1 and RAEB-2 groups were significantly lower than that in the controls(P <0.05). The mRNA expressions of TIN2 in high-risk group, inter risk-2 group and inter risk-1 group according to the international prognostic scoring system criteria were significantly higher than that in controls(P <0. 05). There was no significant difference between low risk group and the control group. The mRNA expressions of POT1 in high risk group, inter-risk-2 group and inter-risk-1 group were significantly lower than the controls(P <0.05). There was no significant difference between low risk group and the control group. The mRNA expression of TIN2 in normal chromatosome group was significantly lower than that in abnormal chromatosome group (P <0.05). There was no significant difference between normal chromatosome group and the control group. The mRNA expression of POT1 in normal chromatosome group was significantly higher than that in abnormal chromatosome group (P < 0. 05). There was no significant difference between normal chromatosome group and the control group. It is concluded that the abnormal mRNA expression of TIN2 and POT1 may be involved in the regulation of telomere dynamics of MDS patients, the regulatory mechanism may be related to the telomere length and the pathogenesis of MDS.%本研究旨在探讨端粒保护蛋白TIN2、POT1的mRNA表达与骨髓增生异常综合征(MDS)发病的关系.采用实时荧光定量PCR方法检测51例初发MDS患者和10例正常人端粒保护蛋白TIN2和POT1的mRNA表达情况.结果表明,WHO分组中RA/RARS/RCMD/MDS-U、RAEB-1及RAEB-2组TIN2 mRNA的表达量均高于正常对照组,差异有显著性(P＜ 0.05)；RA/RARS/RCMD/MDS-U、RAEB-1及RAEB-2组POT1 mRNA的表达量均低于正常对照组,差异有显著性(P＜0.05).IPSS分组中,TIN2 mRNA的表达量在高危组、中危-2及中危-1均高于对照组,差异有显著性(P＜0.05),低危组与对照组间差异没有显著性；POTl mRNA的表达量在高危组、中危-2及中危-1均低于对照组,差异有显著性(P＜0.05),低危组与对照组间差异没有显著性.MDS中正常染色体核型患者TIN2 mRAN的表达量低于异常染色体核型的患者,与对照组相比差异没有显著性；MDS中正常染色体核型患者POT1 mRAN的表达量高于异常染色体核型的患者,与对照组相比差异没有显著性.结论:TIN2、POT1 mRNA的表达异常可能参与MDS患者端粒动力学的调节,引起MDS患者端粒长度的改变,进而导致疾病的发生.